Home » AGEB Journal » Issues » Volume 80" » Fasc.4 - Original articles » Article details

A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update

Journal Volume 80 - 2017
Issue Fasc.4 - Original articles
Author(s) R. Dumont, F. Puleo, J. Collignon, N. Meurisse, M. Chavez, L. Seidel, P. Gast, M. Polus, C. Loly, Ph. Delvenne, P. Meunier, R. Hustinx, A. Deroover, O. Detry, E. Louis, Ph. Martinive, D. Van Daele
Full article This article has been withdrawn by the authors because of incorrect authorship, which is considered a form of unethical publication. The editorial board gave its approval to retract the manuscript.
(1) Gastroenterology and Medical Oncology, Digestive Oncology Clinic, CHU Sart Tilman, Liège, Belgium ; (2) Digestive Oncology, Jules Bordet Institute, ULB, Brussels, Belgium ; (3) Digestive Surgery, CHU Sart Tilman, Liège, Belgium ; (4) Clinical Hematology, CHU Sart Tilman, Liège, Belgium ; (5) Biostatistics, SIME, CHU Sart Tilman, Liège, Belgium ; (6) Anatomopathology, CHU Sart Tilman, Liège, Belgium ; (7) Medical Imaging, CHU Sart Tilman, Liège, Belgium ; (8) Radiotherapy, CHU Sart Tilman, Liège, Belgium.

Background and study aims : The current standard of care for resectable pancreatic ductal adenocarcinoma (PDAC) is surgery- first followed by adjuvant chemotherapy. We review our single center experience in a PDAC cohort managed by the surgery- first strategy. We then compare our data to those of Belgian and international literature. Patients and methods : We reviewed a series of 83 consecutive resectable patients with PDAC, treated by the surgery- first approach in a Belgian Academic Hospital between 2007 and 2013. The outcomes were assessed with univariate and multivariate Cox regression analysis. Kaplan-Meier curves were drawn according to patient groups. Results : For the entire population, the median survival (MS) was 18.4 months; the 1-year relapse-free survival was 56%, and the 5-year overall survival (OS) was 13%. The size of the primary tumor larger than 3 cm (OS, HR = 1.76, p = 0.033) and vascular resection (DFS, HR = 2.1, p = 0.024) were the single independent prognostic factors in the multivariate analysis of this cohort.

© Acta Gastro-Enterologica Belgica.
PMID 29560639